# Efficacy and Safety In Poorly Controlled Type 2 Diabetics

> **NCT00044460** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 142 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00044460
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-04-10
- **Final completion:** 2003-04-10
- **Target enrollment:** 142 (—)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044460, "Efficacy and Safety In Poorly Controlled Type 2 Diabetics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00044460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*